Skip to content
Homepage
Author:
Spur Therapeutics
Posted Date:
July 14, 2026
Spur Therapeutics Announces Executive Transitions
Spur Therapeutics
July 14, 2026
Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1
Spur Therapeutics
July 7, 2026
Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
Spur Therapeutics
May 4, 2026
Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
Spur Therapeutics
April 21, 2026
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
Spur Therapeutics
February 4, 2026
